Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. Cascadian Therapeutics' clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. Cascadian Therapeutics completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Cascadian Therapeutics was founded in 2007 and is headquartered in Seattle, US

Cascadian Therapeutics has an office in Seattle

Seattle, US (HQ)

500 2601 4th Ave

USD

## Net income (Q1, 2017) | (11.4 m) |

## EBIT (Q1, 2017) | (11.6 m) |

## Market capitalization (20-Jul-2017) | 199.4 m |

## Closing share price (20-Jul-2017) | 4.1 |

## Cash (31-Mar-2017) | 35.7 m |

Cascadian Therapeutics's current market capitalization is $199.4 m.

USD | FY, 2016^{} |
---|---|

## R&D expense | 27.5 m |

## General and administrative expense | 17.6 m |

## Operating expense total | 64.8 m |

## EBIT | (64.8 m) |

## Pre tax profit | (64.6 m) |

## Income tax expense | (6.9 m) |

## Net Income | (57.7 m) |

USD | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|

## R&D expense | 5.7 m | 5.8 m | 5.7 m | 5.1 m | 6.3 m | 6.4 m | 7.3 m | 8.6 m |

## General and administrative expense | 2.4 m | 2.3 m | 2.6 m | 2.1 m | 6.6 m | 4.4 m | 3.5 m | 3 m |

## Operating expense total | 8 m | 8.1 m | 8.3 m | 7.2 m | 13 m | 10.7 m | 10.8 m | 11.6 m |

## EBIT | (8 m) | (8.1 m) | (8.3 m) | (7.2 m) | (13 m) | (30.5 m) | (10.8 m) | (11.6 m) |

## Pre tax profit | (30.4 m) | (10.8 m) | ||||||

## Income tax expense | (6.9 m) | |||||||

## Net Income | (6.7 m) | (7.9 m) | (10.9 m) | (4.6 m) | (12.9 m) | (23.5 m) | (10.8 m) | (11.4 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 9.3 m | 10.5 m | 27.9 m | 13.7 m |

## Current Assets | 60.9 m | 58.9 m | 58 m | 64.5 m |

## PP&E | 1.7 m | 1.6 m | 1.8 m | 1.4 m |

## Goodwill | 2.1 m | 16.7 m | 16.7 m | 16.7 m |

## Total Assets | 77.7 m | 103.4 m | 96.6 m | 83.3 m |

## Accounts Payable | 533 k | 689 k | 439 k | 824 k |

## Current Liabilities | 4.7 m | 4.7 m | 4.8 m | 8.8 m |

## Common Stock | 353.8 m | |||

## Additional Paid-in Capital | 154.8 m | 224.5 m | 249.6 m | 297.9 m |

## Retained Earnings | (432.1 m) | (482 m) | (514.6 m) | (572.3 m) |

## Total Equity | 83.7 m | 74.4 m | ||

## Financial Leverage | 1.2 x | 1.1 x |

USD | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|

## Cash | 34.2 m | 13.5 m | 12.9 m | 25.3 m | 13.9 m | 51 m | 16.6 m | 35.7 m |

## Current Assets | 82 m | 75 m | 70.8 m | 64.4 m | 48.2 m | 81.8 m | 73.1 m | 127.8 m |

## PP&E | 1.7 m | 1.9 m | 1.8 m | 1.9 m | 1.7 m | 1.6 m | 1.3 m | 1.7 m |

## Goodwill | 16.7 m | 16.7 m | 16.7 m | 16.7 m | 16.7 m | 16.7 m | 16.7 m | 16.7 m |

## Total Assets | 130.9 m | 117.3 m | 109.6 m | 103.2 m | 87.1 m | 100.8 m | 91.8 m | 157.2 m |

## Accounts Payable | 303 k | 497 k | 353 k | 389 k | 832 k | 1.3 m | 741 k | 1 m |

## Current Liabilities | 4.7 m | 3.6 m | 5.9 m | 3.5 m | 5.5 m | 6.3 m | 7.4 m | 5.4 m |

## Common Stock | 353.9 m | 353.9 m | ||||||

## Additional Paid-in Capital | 224.1 m | 247.5 m | 248.2 m | 248.7 m | 252.5 m | 296.5 m | 297.3 m | 386.7 m |

## Retained Earnings | (454.5 m) | (490 m) | (500.9 m) | (505.5 m) | (527.5 m) | (551 m) | (561.8 m) | (583.7 m) |

## Total Equity | 96.1 m | 92.1 m | 73.8 m | 94.3 m | 84.3 m | 151.7 m | ||

## Financial Leverage | 1.1 x | 1.1 x | 1.2 x | 1.1 x | 1.1 x | 1 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (38.8 m) | (50 m) | (32.6 m) | (57.7 m) |

## Depreciation and Amortization | 489 k | 512 k | 613 k | 642 k |

## Accounts Payable | (600 k) | 144 k | (250 k) | 385 k |

## Cash From Operating Activities | (36.3 m) | (48.4 m) | (28.9 m) | (36.8 m) |

## Purchases of PP&E | (252 k) | (380 k) | (771 k) | (147 k) |

## Cash From Investing Activities | (2.7 m) | 9.2 m | 23.7 m | (21 m) |

## Cash From Financing Activities | 26.1 m | 40.4 m | 22.6 m | 43.6 m |

## Interest Paid | 276 k |

USD | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|

## Net Income | (6.7 m) | (7.9 m) | (10.9 m) | (4.6 m) | (12.9 m) | (23.5 m) | (10.8 m) | (11.4 m) |

## Accounts Payable | 303 k | 497 k | 353 k | 389 k | 832 k | 1.3 m | 741 k | 1 m |

Y, 2017 | |
---|---|

## Financial Leverage | 1 x |